An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Paragon 28, Inc. to report financial results for Q3 2023
Positive
Investors can listen to the conference call for Q3 2023 financial results
Negative
None.
ENGLEWOOD, Colo.--(BUSINESS WIRE)--
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (646-904-5544) for international callers, using conference ID: 308457. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.
Investor Contact:
Matthew Brinckman
Senior Vice President, Strategy and Investor Relations
Phone: (720) 912-1332
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
FAQ
When will Paragon 28, Inc. report its financial results for Q3 2023?
Paragon 28, Inc. will report its financial results for Q3 2023 after market close on Tuesday, November 7, 2023.
How can investors listen to the conference call?
Investors can listen to the conference call by dialing (833-470-1428) for domestic callers or (646-904-5544) for international callers, using conference ID: 308457.
Where can I find the webcast of the conference call?
The live audio of the webcast will be available on the 'Investors' section of the company's website at ir.paragon28.com.
How long will the webcast be available for replay?
The webcast will be archived and available for replay for at least 90 days after the event.
